High Intravascular Signal Arterial Transit Time Artifacts Have Negligible Effects on Cerebral Blood Flow and Cerebrovascular Reserve Capacity Measurement Using Single Postlabel Delay Arterial Spin-Labeling in Patients with Moyamoya Disease

References

1. 1.↵
   1. Kuroda S,
   2. Houkin K

   . Moyamoya disease: current concepts and future perspectives. Lancet Neurol 2008;7:1056–66 doi:10.1016/S1474-4422(08)70240-0 pmid:18940695

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Lee S,
   2. Yun TJ,
   3. Yoo RE, et al

   . Monitoring cerebral perfusion changes after revascularization in patients with Moyamoya disease by using arterial spin-labeling MR imaging. Radiology 2018;288:565–72 doi:10.1148/radiol.2018170509 pmid:29714677

   CrossRefPubMed
3. 3.↵
   1. Zaharchuk G,
   2. Do HM,
   3. Marks MP, et al

   . Arterial spin-labeling MRI can identify the presence and intensity of collateral perfusion in patients with Moyamoya disease. Stroke 2011;42:2485–91 doi:10.1161/STROKEAHA.111.616466 pmid:21799169

   Abstract/FREE Full Text
4. 4.↵
   1. Vagal AS,
   2. Leach JL,
   3. Fernandez-Ulloa M, et al

   . The acetazolamide challenge: techniques and applications in the evaluation of chronic cerebral ischemia. AJNR Am J Neuroradiol 2009;30:876–84 doi:10.3174/ajnr.A1538 pmid:19246526

   Abstract/FREE Full Text
5. 5.↵
   1. Noguchi T,
   2. Kawashima M,
   3. Nishihara M, et al

   . Noninvasive method for mapping CVR in Moyamoya disease using ASL-MRI. Eur J Radiol 2015;84:1137–43 doi:10.1016/j.ejrad.2015.03.011 pmid:25816991

   CrossRefPubMed
6. 6.↵
   1. Inoue Y,
   2. Tanaka Y,
   3. Hata H, et al

   . Arterial spin-labeling evaluation of cerebrovascular reactivity to acetazolamide in healthy subjects. AJNR Am J Neuroradiol 2014;35:1111–16 doi:10.3174/ajnr.A3815 pmid:24371025

   Abstract/FREE Full Text
7. 7.↵
   1. Zaharchuk G

   . Arterial spin-labeling for acute stroke: practical considerations. Transl Stroke Res 2012;3:228–35 doi:10.1007/s12975-012-0159-8 pmid:24323778

   CrossRefPubMed
8. 8.↵
   1. Alsop DC,
   2. Detre JA,
   3. Golay X, et al

   . Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: a consensus of the ISMRM Perfusion Study Group and the European Consortium for ASL in Dementia. Magn Reson Med 2015;73:102–16 doi:10.1002/mrm.25197 pmid:24715426

   CrossRefPubMed
9. 9.↵
   1. Fan AP,
   2. Guo J,
   3. Khalighi MM, et al

   . Long-delay arterial spin labeling provides more accurate cerebral blood flow measurements in Moyamoya patients: a simultaneous positron emission tomography/MRI study. Stroke 2017;48:2441–49 doi:10.1161/STROKEAHA.117.017773 pmid:28765286

   Abstract/FREE Full Text
10. 10.↵
    1. Mutke MA,
    2. Madai VI,
    3. von Samson-Himmelstjerna FC, et al

    . Clinical evaluation of an arterial-spin-labeling product sequence in steno-occlusive disease of the brain. PLoS One 2014;9:e87143 doi:10.1371/journal.pone.0087143 pmid:24516546

    CrossRefPubMed
11. 11.↵
    1. Chng SM,
    2. Petersen ET,
    3. Zimine I, et al

    . Territorial arterial spin labeling in the assessment of collateral circulation: comparison with digital subtraction angiography. Stroke 2008;39:3248–54 doi:10.1161/STROKEAHA.108.520593 pmid:18845805

    Abstract/FREE Full Text
12. 12.↵
    1. Buxton RB,
    2. Frank LR,
    3. Wong EC, et al

    . A general kinetic model for quantitative perfusion imaging with arterial spin-labeling. Magn Reson Med 1998;40:383–96 doi:10.1002/mrm.1910400308 pmid:9727941

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Lindig T,
    2. Kotikalapudi R,
    3. Schweikardt D, et al

    . Evaluation of multimodal segmentation based on 3D T1-, T2- and FLAIR-weighted images: the difficulty of choosing. Neuroimage 2018;170:210–21 doi:10.1016/j.neuroimage.2017.02.016 pmid:28188918

    CrossRefPubMed
14. 14.↵
    1. Mutsaerts HJ,
    2. van Dalen JW,
    3. Heijtel DF, et al

    . Cerebral perfusion measurements in elderly with hypertension using arterial-spin labeling. PLoS One 2015;10:e0133717 doi:10.1371/journal.pone.0133717 pmid:26241897

    CrossRefPubMed
15. 15.↵
    1. Tatu L,
    2. Moulin T,
    3. Bogousslavsky J, et al

    . Arterial territories of the human brain: cerebral hemispheres. Neurology 1998;50:1699–1708 doi:10.1212/wnl.50.6.1699 pmid:9633714

    Abstract/FREE Full Text
16. 16.↵
    1. Chen Y,
    2. Wang DJ,
    3. Detre JA

    . Test-retest reliability of arterial spin-labeling with common labeling strategies. J Magn Reson Imaging 2011;33:940–49 doi:10.1002/jmri.22345 pmid:21448961

    CrossRefPubMed
17. 17.↵
    1. Petr J,
    2. Schramm G,
    3. Hofheinz F, et al

    . Partial volume correction in arterial spin-labeling using a Look-Locker sequence. Magn Reson Med 2013;70:1535–43 doi:10.1002/mrm.24601 pmid:23280559

    CrossRefPubMed
18. 18.↵
    1. Wu WC,
    2. Jiang SF,
    3. Yang SC, et al

    . Pseudocontinuous arterial spin labeling perfusion magnetic resonance imaging: a normative study of reproducibility in the human brain. Neuroimage 2011;56:1244–50 doi:10.1016/j.neuroimage.2011.02.080 pmid:21385620

    CrossRefPubMed
19. 19.↵
    1. Andaluz N,
    2. Choutka O,
    3. Vagal A, et al

    . Patient selection for revascularization procedures in adult Moyamoya disease based on dynamic perfusion computerized tomography with acetazolamide challenge (PCTA). Neurosurg Rev 2010;33:225–32; discussion 232–33 doi:10.1007/s10143-010-0237-x pmid:20140634

    CrossRefPubMed
20. 20.↵
    1. Detre JA,
    2. Samuels OB,
    3. Alsop DC, et al

    . Noninvasive magnetic resonance imaging evaluation of cerebral blood flow with acetazolamide challenge in patients with cerebrovascular stenosis. J Magn Reson Imaging 1999;10:870–75 doi:10.1002/(SICI)1522-2586(199911)10:5<870::AID-JMRI36>3.0.CO;2-D pmid:10548801

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Federau C,
    2. Christensen S,
    3. Zun Z, et al

    . Cerebral blood flow, transit time, and apparent diffusion coefficient in Moyamoya disease before and after acetazolamide. Neuroradiology 2017;59:5–12 doi:10.1007/s00234-016-1766-y pmid:27913820

    CrossRefPubMed
22. 22.↵
    1. Ni WW,
    2. Christen T,
    3. Rosenberg J, et al

    . Imaging of cerebrovascular reserve and oxygenation in Moyamoya disease. J Cereb Blood Flow Metab 2017;37:1213–22 doi:10.1177/0271678X16651088 pmid:27207169

    CrossRefPubMed
23. 23.↵
    1. Noguchi T,
    2. Kawashima M,
    3. Irie H, et al

    . Arterial spin-labeling MR imaging in moyamoya disease compared with SPECT imaging. Eur J Radiol 2011;80:e557–62 doi:10.1016/j.ejrad.2011.01.016 pmid:21315533

    CrossRefPubMed
24. 24.↵
    1. Yun TJ,
    2. Paeng JC,
    3. Sohn CH, et al

    . Monitoring cerebrovascular reactivity through the use of arterial spin labeling in patients with Moyamoya disease. Radiology 2016;278:205–13 doi:10.1148/radiol.2015141865 pmid:26197057

    CrossRefPubMed
25. 25.↵
    1. Martin SZ,
    2. Madai VI,
    3. von Samson-Himmelstjerna FC, et al

    . 3D GRASE pulsed arterial spin labeling at multiple inflow times in patients with long arterial transit times: comparison with dynamic susceptibility-weighted contrast-enhanced MRI at 3 Tesla. J Cereb Blood Flow Metab 2015;35:392–401 doi:10.1038/jcbfm.2014.200 pmid:25407272

    CrossRefPubMed
26. 26.↵
    1. Donahue MJ,
    2. Achten E,
    3. Cogswell PM, et al

    . Consensus statement on current and emerging methods for the diagnosis and evaluation of cerebrovascular disease. J Cereb Blood Flow Metab 2018;38:1391–1417 doi:10.1177/0271678X1772183]0 pmid:28816594

    CrossRefPubMed
27. 27.↵
    1. Eskey CJ,
    2. Sanelli PC

    . Perfusion imaging of cerebrovascular reserve. Neuroimaging Clin N Am 2005;15:367–81, xi doi:10.1016/j.nic.2005.05.002 pmid:16198946

    CrossRefPubMed
28. 28.↵
    1. Lee M,
    2. Zaharchuk G,
    3. Guzman R, et al

    . Quantitative hemodynamic studies in Moyamoya disease: a review. Neurosurg Focus 2009;26:E5 doi:10.3171/2009.1.FOCUS08300 pmid:19335131

    CrossRefPubMed
29. 29.↵
    1. Hara S,
    2. Tanaka Y,
    3. Ueda Y, et al

    . Noninvasive evaluation of CBF and perfusion delay of Moyamoya disease using arterial spin-labeling MRI with multiple postlabeling delays: comparison with (15)O-Gas PET and DSC-MRI. AJNR Am J Neuroradiol 2017;38:696–702 doi:10.3174/ajnr.A5068 pmid:28209582

    Abstract/FREE Full Text
30. 30.↵
    1. Sugino T,
    2. Mikami T,
    3. Miyata K, et al

    . Arterial spin-labeling magnetic resonance imaging after revascularization of Moyamoya disease. J Stroke Cerebrovasc Dis 2013;22:811–16 doi:10.1016/j.jstrokecerebrovasdis.2012.05.010 pmid:22721824

    CrossRefPubMed
31. 31.↵
    1. Goetti R,
    2. Warnock G,
    3. Kuhn FP, et al

    . Quantitative cerebral perfusion imaging in children and young adults with Moyamoya disease: comparison of arterial spin-labeling-MRI and H(2)[(15)O]-PET. AJNR Am J Neuroradiol 2014;35:1022–28 doi:10.3174/ajnr.A3799 pmid:24335546

    Abstract/FREE Full Text
32. 32.↵
    1. Boellaard R,
    2. van Lingen A,
    3. van Balen SC, et al

    . Characteristics of a new fully programmable blood sampling device for monitoring blood radioactivity during PET. Eur J Nucl Med 2001;28:81–89 doi:10.1007/s002590000405 pmid:11202456

    CrossRefPubMed
33. 33.↵
    1. Koopman T,
    2. Yaqub M,
    3. Heijtel DF, et al

    . Semi-quantitative cerebral blood flow parameters derived from non-invasive [(15)O]H2O PET studies. J Cereb Blood Flow Metab 2019;39:163–72 doi:10.1177/0271678X17730654 pmid:28901822

    CrossRefPubMed
34. 34.↵
    1. Khalighi MM,
    2. Deller TW,
    3. Fan AP, et al

    . Image-derived input function estimation on a TOF-enabled PET/MR for cerebral blood flow mapping. J Cereb Blood Flow Metab 2018;38:126–35 doi:10.1177/0271678X17691784 pmid:28155582

    CrossRefPubMed
35. 35.↵
    1. Blauwblomme T,
    2. Lemaitre H,
    3. Naggara O, et al

    . Cerebral blood flow improvement after indirect revascularization for pediatric Moyamoya disease: a statistical analysis of arterial spin-labeling MRI. AJNR Am J Neuroradiol 2016;37:706–12 doi:10.3174/ajnr.A4592 pmid:26585258

    Abstract/FREE Full Text
36. 36.↵
    1. Wang R,
    2. Yu S,
    3. Alger JR, et al

    . Multi-delay arterial spin labeling perfusion MRI in Moyamoya disease–comparison with CT perfusion imaging. Eur Radiol 2014;24:1135–44 doi:10.1007/s00330-014-3098-9 pmid:24557051

    CrossRefPubMed
37. 37.↵
    1. Choi HJ,
    2. Sohn CH,
    3. You SH, et al

    . Can arterial spin-labeling with multiple postlabeling delays predict cerebrovascular reserve? AJNR Am J Neuroradiol 2018;39:84–90 doi:10.3174/ajnr.A5439 pmid:29146719

    Abstract/FREE Full Text
38. 38.↵
    1. Ahlgren A,
    2. Wirestam R,
    3. Lind E, et al

    . A linear mixed perfusion model for tissue partial volume correction of perfusion estimates in dynamic susceptibility contrast MRI: impact on absolute quantification, repeatability, and agreement with pseudo-continuous arterial spin labeling. Magn Reson Med 2017;77:2203–14 doi:10.1002/mrm.26305 pmid:27321696

    CrossRefPubMed